CNS Appoints Leading Toxicologist Douglas Francis to BioDesk
News Mar 04, 2013
Clinical Network Services (CNS) has announced that it has appointed ex-Therapeutic Goods Administration (TGA) toxicologist, Dr Douglas Francis, as Senior Regulatory Toxicologist to the Company’s BioDesk product development planning and regulatory affairs service.
In his new role, Dr Francis will be providing advice and assistance to international and Australian/New Zealand biotechnology companies in the areas of toxicology, pharmacology, and drug optimization in support of the conduct of clinical trials and drug registration in key global markets.
Dr Francis is a UK/European registered toxicologist and is a member of a number of international bodies including the US Society of Toxicology (SOT) by review, the American College of Toxicology (ACT), the British Toxicology Society (BTS) and the Roundtable of Toxicology Consultants.
He originally studied Veterinary Science at the University of Sydney followed by a PhD at the University of Sydney and was, for a number of years, a clinical academic at the University of Sydney and the University of Melbourne.
Most recently, Dr Francis offered regulatory toxicology services to small to medium pharmaceutical and biotech clients in Australia, Europe and the USA through his own consultancy, DF Pre-clinical Services Pty Ltd.
Previous to that, he was the Vice President of Drug Development for the Australian biotechnology company, Phylogica Pty Ltd, and from 1998-2006, Drug Development Manager at Pharmaxis Ltd where he managed many of the company’s pre-clinical programs.
This latter role led to him to gain worldwide product marketing authorizations for these programs in key global markets. Dr Francis was a Senior Toxicologist at the TGA from 1995-1997, and was part of a research team at the John Curtin School of Medical Research, Australian National University, Canberra, Australia from 1998-2001.
Mark Reid, Associate Director, BioDesk & Regulatory Affairs, commented: “Dr Francis is arguably the most qualified senior toxicologist for drug development in Australia and has global regulatory toxicological experience in the key pharmaceutical markets of Europe and the USA. We have been working with Doug for a number of years now on a consultancy basis and are looking forward to the merging of his consultancy operations with the BioDesk operation of CNS”.
Mark Ried will be attending the DIA EuroMeeting 2013 in Amsterdam, the Netherlands from the 4th to 6th March and BIOEurope Spring 2013 in Barcelona, Spain on 11th to 13th March 2013.
More than 60 years after the drug thalidomide caused birth defects in thousands of children whose mothers took the drug while pregnant, scientists have solved a mystery that has lingered ever since the dangers of the drug first became apparent: how did the drug produce such severe fetal harm?READ MORE